StockNews.com Initiates Coverage on BioLineRx (NASDAQ:BLRX)

Equities researchers at StockNews.com began coverage on shares of BioLineRx (NASDAQ:BLRX) in a report released on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.

Other research analysts also recently issued research reports about the stock. Jones Trading reissued a “hold” rating on shares of BioLineRx in a research report on Wednesday, April 2nd. HC Wainwright lifted their target price on shares of BioLineRx from $9.00 to $26.00 and gave the stock a “buy” rating in a report on Monday, March 31st.

BioLineRx Stock Up 0.9%

Shares of BLRX stock opened at $3.27 on Friday. The company has a current ratio of 1.52, a quick ratio of 1.37 and a debt-to-equity ratio of 2.11. BioLineRx has a 1 year low of $2.30 and a 1 year high of $35.60. The firm’s fifty day moving average price is $3.06 and its two-hundred day moving average price is $6.29. The firm has a market capitalization of $10.89 million, a P/E ratio of -0.37 and a beta of 1.15.

Institutional Investors Weigh In On BioLineRx

An institutional investor recently bought a new position in BioLineRx stock. Highbridge Capital Management LLC purchased a new stake in BioLineRx Ltd. (NASDAQ:BLRX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned 50.50% of BioLineRx as of its most recent filing with the Securities and Exchange Commission. 1.56% of the stock is owned by institutional investors and hedge funds.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.